Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-13 EDT			5-day change	1st Jan Change
516.20 ^DKK	-0.58%		+5.27%	-17.30%

06:39pm	Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	RE
06-13	Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…

Novo Nordisk Taps Banks for Potential Bond Issue

Published on 2024-05-13 at 11:44, updated on 2024-05-13 at 11:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06:39pm	RE
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	06-13
Odin Norden rose 3.16 percent in May – positive reporting season for portfolio companies	06-13	FW
NOVO NORDISK : Receives a Buy rating from UBS	06-13	ZD
Novo Nordisk Surpasses SAP to Regain Europe's Most Valuable Listed Company Title	06-13	MT
Novo Nordisk regains crown as Europe's most valuable company	06-13	RE
Novo Nordisk regains crown as Europe's most valuable company	06-13	RE
Novo Nordisk is once again the highest valued listed company in Europe.	06-13	FW
Novo Nordisk: amycretin progresses to Phase 3	06-13	CF
SEB Sweden Equity Fund increased by 2.8 percent in May – divested its holding in Vitrolife	06-13	FW
Novo Nordisk takes amycretin for overweight into phase 3	06-13	FW
Novo Nordisk to Launch Late-stage Development of Amycretin Weight Management Treatment	06-12	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-12	MT
Sector Update: Health Care	06-12	MT
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	06-12	RE
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	06-12	RE
Novo Nordisk Plans Phase 3 Clinical Development of Amycretin for Weight Management	06-12	MT
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin	06-12	RE
Novo Nordisk Says Planning To Initiate A Phase 3 Development Programme With Amycretin For Adults With Overweight Or Obesity During Q1 Of 2026	06-12	RE
Novo Nordisk to Advance Subcutaneous and Oral Amycretin for Weight Management into Phase 3 Clinical Development	06-12	CI
India's OneSource eyes weight-loss drug boost to order book	06-12	RE
NOVO NORDISK : Bernstein remains Neutral	06-12	ZD
Allarity Therapeutics, Inc Announces Changes to Board of Directors	06-11	CI
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	06-11	RE
Top Midday Stories: Trump Says China Trade Deal 'Done;' US May Inflation Lower Than Expected	06-11	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06-20 - American Diabetes Association Scientific Conference - Oral Presentation: 86-OR

More about the company